Primary Care Identification Of Patients With Chronic Neuropathic Low Back Pain Study
Status:
Withdrawn
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
A0081256 is a prospective, open-label, multi-centre European study designed to raise
awareness and enhance the diagnosis of patients with chronic low back pain with a neuropathic
pain component in primary care who are refractory to standard analgesic therapy and/or one
treatment for neuropathic pain and evaluate the effectiveness and tolerability of pregabalin
in this population. The impact of pregabalin on analgesia, patient satisfaction with
treatment, patient anxiety and depression, sleep interference, physical functioning and work
productivity will be assessed.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.